Quantitative determination of erlotinib and O-desmethyl erlotinib in human EDTA plasma and lung tumor tissue

Bioanalysis

Volumn 4, Issue 21, 2012, Pages 2563-2577

  Lankheet, N A G ^a   Schaake, E E ^b   Rosing, H ^a   Burgers, J A ^b   Schellens, J H M ^b,c   Beijnen, J H ^a,c   Huitema, A D R ^a  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b NETHERLANDS CANCER INSTITUTE   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; EDETIC ACID; ERLOTINIB; ERLOTINIB C 13; O DESMETHYL ERLOTINIB; OSI 420; UNCLASSIFIED DRUG;

ARTICLE; CALIBRATION; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG DOSE REGIMEN; DRUG STRUCTURE; DRUG TISSUE LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MASS SPECTROMETRY; PROCESS DEVELOPMENT; QUANTITATIVE ANALYSIS; SENSITIVITY ANALYSIS; TISSUE HOMOGENATE; VALIDATION PROCESS;

CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; EDETIC ACID; HUMANS; LUNG NEOPLASMS; MOLECULAR STRUCTURE; QUINAZOLINES; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY;

EID: 84870218283     PISSN: 17576180     EISSN: 17576199     Source Type: Journal    
DOI: 10.4155/bio.12.235     Document Type: Article

References (17)

1. Thomas F, Rochaix P, White-Koning M et al. Population pharmacokinetics of erlotinib and its pharmacokinetic/pharmacodynamic relationships in head and neck squamous cell carcinoma. Eur. J. Cancer 45(13), 2316-2323 (2009).
2. Hidalgo M, Siu LL, Nemunaitis J et al. Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J. Clin. Oncol. 19(13), 3267-3279 (2001). (Pubitemid 32591445)
3. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N. Engl. J. Med. 353(2), 123-132 (2005). (Pubitemid 41058344)
4. Li T, Ling YH, Goldman ID, Perez-Soler R. Schedule-dependent cytotoxic synergism of pemetrexed and erlotinib in human non-small cell lung cancer cells. Clin. Cancer Res. 13(11), 3413-3422 (2007). (Pubitemid 46944930)
5. Davies AM, Ho C, Lara PN Jr, Mack P, Gumerlock PH, Gandara DR. Pharmacodynamic separation of epidermal growth factor receptor tyrosine kinase inhibitors and chemotherapy in non-small-cell lung cancer. Clin. Lung Cancer 7(6), 385-388 (2006). (Pubitemid 44043547)
6. Lepper ER, Swain SM, Tan AR, Figg WD, Sparreboom A. Liquid- chromatographic determination of erlotinib (OSI-774), an epidermal growth factor receptor tyrosine kinase inhibitor. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 796(1), 181-188 (2003). (Pubitemid 38352722)
7. Masters AR, Sweeney CJ, Jones DR. The quantifcation of erlotinib (OSI-774) and OSI-420 in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 848(2), 379-383 (2007). (Pubitemid 46464049)
8. Zhang W, Siu LL, Moore MJ, Chen EX. Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 814(1), 143-147 (2005). (Pubitemid 40017946)
9. Zhao M, He P, Rudek MA, Hidalgo M, Baker SD. Specifc method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 793(2), 413-420 (2003). (Pubitemid 37271981)
10. Schaake EE, Kappers I, Codrington HE et al. Tumor response and toxicity of neoadjuvant erlotinib in patients with early-stage non-small-cell lung cancer. J. Clin. Oncol. 30(22), 2731-2738 (2012).
11. Viswanathan CT, Bansal S, Booth B et al. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharm. Res. 24(10), 1962-1973 (2007). (Pubitemid 47389236)
12. Liang HR, Foltz RL, Meng M, Bennett P. Ionization enhancement in atmospheric pressure chemical ionization and suppression in electrospray ionization between target drugs and stable-isotope-labeled internal standards in quantitative liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass Spectrom. 17(24), 2815-2821 (2003). (Pubitemid 38029325)
13. Sojo LE, Lum G, Chee P. Internal standard signal suppression by co-eluting analyte in isotope dilution LC-ESI-MS. Analyst 128(1), 51-54 (2003). (Pubitemid 36140340)
14. Dolan JW. Autosampler carry over. LCGC 19(2), 164-168 (2001).
15. Dolan JW. Attacking carry over problems. LCGC 19(10), 1050-1054 (2001).
16. Carey KD, Garton AJ, Romero MS et al. Kinetic ana lysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res. 66(16), 8163-8171 (2006). (Pubitemid 44299184)
17. Sangha R, Davies AM, Lara PN Jr et al. intercalated erlotinib-docetaxel dosing schedules designed to achieve pharmacodynamic separation: results of a Phase I/II trial. J. Thorac. Oncol. 6(12), 2112-2119 (2011).